Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Mar;12(2):147-53.
doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1.

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Affiliations
Randomized Controlled Trial

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial

Michael Anstead et al. J Cyst Fibros. 2013 Mar.

Abstract

Background: The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.

Methods: Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.

Results: Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.

Conclusion: P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of individual antigen titers by concurrent culture status for all 975 serum samples. Pa+ indicates P. aeruginosa positive, Pa− indicates P. aeruginosa negative. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range), whiskers extend to minimum and maximum or 1.5× the inter-quartile range (whichever is smaller), outliers are marked as circles.
Fig. 2
Fig. 2
Culture positivity and seropositivity over time. The solid black line shows the proportion culture positive for P. aeruginosa across each visit among the 303 subjects with available serology. The dashed lines show the proportion of samples seropositive at each visit for each combined ELISA. A combined ELISA is defined as seropositive if any one of the three antigens in an ELISA has titer at least 100.
Fig. 3
Fig. 3
Baseline serology titers by respiratory culture status using modified Leeds criteria. Subjects were classified as ‘Pa free’ if they were clear of P. aeruginosa from baseline through end of study, ‘Intermittent’ if they had less than half of all available cultures testing positive for P. aeruginosa, and ‘Chronic’ if they had half or more of all available cultures testing positive for P. aeruginosa. Hash lines are the median values, boxes represent the 25th and 75th percentiles (inter-quartile range), whiskers extend to minimum and maximum or 1.5× the inter-quartile range (whichever is smaller), outliers are marked as circles.

Similar articles

Cited by

References

    1. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997;23:330–335. - PubMed
    1. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J. 2005;26:458–461. - PubMed
    1. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67–91. - PubMed
    1. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–366. - PubMed
    1. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young childrenwith cystic fibrosis. J Infect Dis. 2001;183:444–452. - PubMed

Publication types

Substances